ALAN WAYNE PARTIN, M.D.
Urology at Caroline St, Baltimore, MD

License number
Maryland D47260
Category
Radiology
Type
Urology
Address
Address
601 N Caroline St, Baltimore, MD 21287
Phone
(410) 955-6100

Personal information

See more information about ALAN WAYNE PARTIN at radaris.com
Name
Address
Phone
Alan Partin
14200 Carroll Ridge Ct, Baldwin, MD 21013
(410) 593-9565
Alan Partin, age 63
6400 Catalpa Rd, Fork, MD 21051
Alan M Partin
6400 Catalpa Rd, Fork, MD 21051
Alan W Partin, age 63
7 Hedgeford Ct, Nottingham, MD 21236

Professional information

Alan Wayne Partin Photo 1

Alan Wayne Partin, Baltimore MD

Specialties:
Urology, Surgery
Work:
The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287 Johns Hopkins Outpatient Center
601 N Caroline St, Baltimore, MD 21287 Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore, MD 21224
Education:
Johns Hopkins University (1989)


Alan Partin Photo 2

Method Of Enriching Rare Cells

US Patent:
5962237, Oct 5, 1999
Filed:
Apr 2, 1997
Appl. No.:
8/832468
Inventors:
Paul O. P. Ts'o - Ellicott City MD
Stephen A. Lesko - Baltimore MD
William G. Nelson - Towson MD
Alan W. Partin - Baltimore MD
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
G01N 33574, G01N 3353, G01N 930, B01D 3315
US Classification:
435 723
Abstract:
A method for enriching cancer cells such as prostate cancer cells in a bodily fluid sample is disclosed comprising (a) obtaining the sample comprising cancer cells and non-rare cells; (b) subjecting the sample to multiple density gradient separation comprising a first density gradient and a second density gradient, wherein the second density gradient is greater than the first density gradient, and producing a first fluid comprising an increased concentration of cancer cells of a first density, and a second fluid comprising an increased concentration of cancer cells of a second density, wherein the second density is greater than the first density; wherein subjecting the sample to multiple density gradient separation includes producing a plasma layer, a first interface layer, a first gradient layer, a second interface layer, a second gradient layer, and a cell pellet; wherein producing the first fluid includes combining the first interface layer and the first gradient layer and forming a first suspension; and wherein producing the second fluid includes combining the second interface layer and the second gradient layer and forming a second suspension; (c) subjecting said second fluid comprising the second suspension to a binding agent that binds non-rare cells; and (d) removing the bound non-rare cells from the second fluid to provide a second fluid enriched with the greater density cancer cells.


Alan Partin Photo 3

Nuclear Matrix Proteins

US Patent:
6030793, Feb 29, 2000
Filed:
Feb 23, 1999
Appl. No.:
9/256428
Inventors:
Donald S. Coffey - Lutherville MD
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Branford CT
Assignee:
The John Hopkins University School of Medicine
International Classification:
C07K 1618, C12Q 100, G01N 3353
US Classification:
435 71
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.


Alan Partin Photo 4

Nuclear Matrix Proteins

US Patent:
2002016, Nov 14, 2002
Filed:
Oct 20, 1998
Appl. No.:
09/175230
Inventors:
DONALD S. COFFEY - LUTHERVILLE MD, US
ALAN W. PARTIN - BALTIMORE MD, US
ROBERT H. GETZENBERG - PITTSBURGH PA, US
International Classification:
G01N033/574
US Classification:
435/007230
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.


Alan Partin Photo 5

Nuclear Matrix Proteins

US Patent:
2003014, Jul 31, 2003
Filed:
Jan 29, 2003
Appl. No.:
10/354480
Inventors:
Donald Coffey - Lutherville MD, US
Alan Partin - Baltimore MD, US
Robert Getzenberg - Pittsburgh PA, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.


Alan Partin Photo 6

Method For Detecting Prostate Cancer Using A Reagent Which Binds Prostate Cancer-1 Protein

US Patent:
5824490, Oct 20, 1998
Filed:
May 31, 1995
Appl. No.:
8/455558
Inventors:
Donald S. Coffey - Lutherville MD
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Pittsburgh PA
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
G01N 33574, G01N 3353
US Classification:
435 723
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. Also provided is an in vitro method for detecting prostate cancer in a sample employing a reagent that reacts with the NMP designated PC-1 (prostate cancer-1).


Alan Partin Photo 7

Method Of Enriching Rare Cells

US Patent:
2003011, Jun 26, 2003
Filed:
Oct 25, 2002
Appl. No.:
10/281043
Inventors:
Paul Ts'o - Ellicot City MD, US
Stephen Lesko - Baltimore MD, US
William Nelson - Towson MD, US
Alan Partin - Baltimore MD, US
Assignee:
John Hopkins University School of Medicine - Baltimore MD
International Classification:
G01N033/567, G01N033/574, C12N005/08
US Classification:
435/007210, 435/007230, 435/366000
Abstract:
The present invention provides for enriching rare cells in a fluid comprising the rare cells and non-rare cells. Examples of rare cells enriched include prostate cancer cells.


Alan Partin Photo 8

Nuclear Matrix Proteins

US Patent:
2006017, Aug 3, 2006
Filed:
Apr 6, 2006
Appl. No.:
11/400698
Inventors:
Donald Coffey - Lutherville MD, US
Alan Partin - Baltimore MD, US
Robert Getzenberg - Pittsburgh PA, US
International Classification:
G01N 33/574
US Classification:
435007230
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.


Alan Partin Photo 9

Nuclear Matrix Proteins

US Patent:
5849509, Dec 15, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/488036
Inventors:
Donald S. Coffey - Lutherville MD
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Branford MD
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
G01N 33574, G01N 3353
US Classification:
435 723
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.


Alan Partin Photo 10

Antibodies To Nuclear Matrix Proteins

US Patent:
5874539, Feb 23, 1999
Filed:
Jun 2, 1995
Appl. No.:
8/459023
Inventors:
Donald S. Coffey - Lutherville MD
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Branford CT
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
C07K 1618
US Classification:
5303871
Abstract:
Antibodies directed to nuclear matrix proteins (NMP) are provided. Such antibodies are useful markers in diagnosing and monitoring the stage of malignancy of a cell.